Citations

Showing 10 of 108081 citations.

Exclusion of Eligible Indeterminate Thyroid Nodules in Estimates of Negative Predictive Value for the Gene Expression Classifier
Rahilly‐Tierney, Catherine , Gharib, Hossein, Duh, Quan‐Yang

Mayo Clinic

JAMA Otolaryngology–Head & Neck Surgery | April 27, 2017 | Volume: 143 | Issue: 7 | Pages: 737

10.1001/jamaoto.2017.0249 | PMID 28448653 Get It

Intersection of diverse neuronal genomes and neuropsychiatric disease: The Brain Somatic Mosaicism Network
McConnell, Michael J. , Moran, John V. , Abyzov, Alexej , Akbarian, Schahram , Bae, Taejeong , Cortés‐Ciriano, Isidro , Erwin, Jennifer A. , Fasching, Liana , Flasch, Diane A. , Freed, Donald , Ganz, Javier , Jaffe, Andrew E. , Kwon, Min‐Seok , Lodato, Michael A. , Mills, Ryan E. , Paquola, Apuã C.M. , Rodin, Rachel E. , Rosenbluh, Chaggai , Šestan, Nenad , Sherman, Maxwell A. , Shin, Joo Heon , Song, Saera , Straub, Richard E. , Thorpe, Jeremy , Weinberger, Daniel R. , Urban, Alexander E. , Zhou, Bo , Lehner, Thomas , Senthil, Geetha , Chess, Andrew , Courchesne, Eric , Gleeson, Joseph G. , Kidd, Jeffrey M. , Park, Peter J., Pevsner, Jonathan , Vaccarino, Flora M. , Network, Brain Somatic Mosaicism, Bekiranov, Stefan , Bohrson, Craig L. , Burbulis, Ian , Chronister, William D., Coppola, Gianfilippo , Daily, Kenneth , D’Gama, Alissa M. , Emery, Sarah B., Frisbie, Trenton J., Gao, Tianliuyun , Gulyás-Kovács, Attila, Haakenson, Mark F., Keil, Jason M. , Lam, Mandy M. , Mathern, Gary W. , Omberg, Larsson , Peters, Mette A. , Pochareddy, Sirisha , Pramparo, Tiziano , Sanavia, Tiziana , Wang, Meiyan , Wierman, Margaret E. , Wolpert, Matthew J., Woodworth, Mollie B. , Zhao, Xuefang , Zhou, Weichen , Kwan, Kenneth Y , Lodato, Michael A , Mills, Ryan E , Paquola, Apua C M , Rodin, Rachel E , Rosenbluh, Chaggai , Sestan, Nenad , Shin, Joo Heon , Song, Saera , Straub, Richard E , Urban, Alexander E , Zhou, Bo , Gage, Fred H , Lehner, Thomas , Senthil, Geetha , Chess, Andrew , Courchesne, Eric , Kidd, Jeffrey M , Pevsner, Jonathan , Vaccarino, Flora M , McConnell, Michael J. , Walsh, Christopher A. , Gleeson, Joseph G. , Network, Brain Somatic Mosaicism, Barton, Alison R. , Kopera, Huira C. , Lee, Eunjung A , Marquès‐Bonet, Tomàs , Moldovan, John B. , Oetjens, Matthew T. , Ratan, Aakrosh , Shi, Lei , Škarica, Mario , Wang, Jia , Wang, Yifan , Abyzov, Alexej , Bae, Taejeong , Akbarian, Schahram

Mayo Clinic

Science | April 27, 2017 | Volume: 356 | Issue: 6336 | Pages: No page available

10.1126/science.aal1641 | PMID 28450582 Get It

Single-cell diversity in the brain The cells that make up an organism may all start from one genome, but somatic mutations mean that somewhere along the line of development, an organism's individual cellular genomes diverge. McConnell et al. review the implications and causes of single-cell genomic diversity for brain function. Somatic mutations caused by mobile genetic elements or errors in DNA repair may underlie certain neuropsychiatric disorders. Science , this issue p. eaal1641
Future Research Opportunities in Peri-Prosthetic Joint Infection Prevention
Berbari, Elie F. , Segreti, John, Berríos-Torres, Sandra I., Berbari, Elie, Parvizi, Javad

Mayo Clinic

Surgical Infections | April 27, 2017 | Volume: 18 | Issue: 4 | Pages: 409-412

10.1089/sur.2017.065 | PMID 28448204 Get It

OS06.1 Genome-wide association study reveals specific differences in genetic susceptibility to glioblastoma and non-glioblastoma
Melin, Beatrice , Kinnersley, Ben , Wrensch, Margaret , Jenkins, Robert B. , Ostrom, Quinn T. , Barnholtz‐Sloan, Jill S. , Houlston, Richard S. , Bondy, Melissa L.

Mayo Clinic

Neuro-Oncology | April 27, 2017 | Volume: 19 | Issue: suppl_3 | Pages: iii10-iii11

10.1093/neuonc/nox036.035 Get It

Optimal utilization of thrombophilia testing
Pruthi, Rajiv K.

Mayo Clinic

International Journal of Laboratory Hematology | April 27, 2017 | Volume: 39 | Issue: S1 | Pages: 104-110

10.1111/ijlh.12672 | PMID 28447412 Get It

AbstractThe global incidence of venous thromboembolism is high so laboratory testing for hereditary thrombophilia and selected acquired thrombophilia is common. Given the costs associated with testing and multiple pre‐analytic and analytic variables affecting the assays, careful patient selection and timing of testing and diligent application to patient management are critical to providing high‐value clinical care. Collaboration between the ordering providers and performing laboratories has the potential to achieve these goals. Herein, utility of thrombophilia testing, variables that affect the assays, and impact on patient management are reviewed. Where available, information on cost‐effectiveness is discussed.
The utility of peripheral blood smear review for identifying specimens for flow cytometric immunophenotyping
Craig, Fiona E.

Mayo Clinic

International Journal of Laboratory Hematology | April 27, 2017 | Volume: 39 | Issue: S1 | Pages: 41-46

10.1111/ijlh.12651 | PMID 28447427 Get It

AbstractLaboratory professionals are in an ideal situation to identify CBC and peripheral blood smear findings that raise the possibility of a hematolymphoid neoplasm, and based on this information make recommendations for additional studies, such as flow cytometric immunophenotyping. In some circumstances a definitive diagnosis can be established from the combined peripheral blood morphologic and immunophenotypic findings obviating the need for bone marrow evaluation, such as for chronic lymphocytic leukemia. Occasionally flow cytometric studies are superior to morphologic assessment, such as in screening for hairy cell leukemia or identifying lymphocytic‐variant hypereosinophilia. However, there is increasing recognition of small immunophenotypically unusual or abnormal populations of peripheral blood cells, particularly in older patients, which are of uncertain clinical significance, such as monoclonal B lymphocytosis and T‐cell clonopathy. Therefore, it is important to integrate peripheral blood smear review findings with the clinical and other information before recommending flow cytometry. In addition, it is important to recognize situations where the results of peripheral blood smear review and flow cytometric immunophenotyping do not explain the clinical findings.
Airway epithelial anion secretion and barrier function following exposure to fungal aeroallergens: role of oxidative stress
Zaidman, Nathan A. , O’Grady, Kelly E., Patil, Nandadevi, Milavetz, Francesca, Maniak, Peter J., Kita, Hirohito , O’Grady, Scott M. , Kita, H

Mayo Clinic

American Journal of Physiology-Cell Physiology | April 27, 2017 | Volume: 313 | Issue: 1 | Pages: C68-C79

10.1152/ajpcell.00043.2017 | PMID 28446427 Get It

Aeroallergens produced by Alternaria alternata can elicit life-threatening exacerbations of asthma in patients sensitized to this fungus. In this study, the effect of Alternaria on ion transport mechanisms underlying mucociliary clearance and airway epithelial barrier function was investigated in human airway epithelial cells. Apical exposure to Alternaria induced an increase in anion secretion that was inhibited by blockers of CFTR and Ca2+-activated Cl− channels. Stimulation of anion secretion was dependent on Ca2+ uptake from the apical solution. Alternaria exposure also produced an increase in reactive oxygen species (ROS) that was blocked by pretreatment with the oxidant scavenger glutathione (GSH). GSH and the NADPH oxidase inhibitor/complex 1 electron transport inhibitor diphenylene iodonium chloride (DPI) blocked ATP release and the increase in intracellular [Ca2+] evoked by Alternaria. Alternaria also decreased transepithelial resistance, and a portion of this effect was dependent on the increase in ROS. However, the Alternaria-induced increase in unidirectional dextran (molecular mass = 4,000 Da) flux across the epithelium could not be accounted for by increased oxidative stress. These results support the conclusion that oxidative stress induced by Alternaria was responsible for regulating Ca2+-dependent anion secretion and tight junction electrical resistance that would be expected to affect mucociliary clearance.
Serologic Testing for Zika Virus: Comparison of Three Zika Virus IgM-Screening Enzyme-Linked Immunosorbent Assays and Initial Laboratory Experiences
Granger, Dane, Hilgart, Heather, Misner, Lori, Christensen, Jaime, Bistodeau, Sarah, Palm, Jennifer, Strain, Anna K., Konstantinovski, Marja, Liu, Dakai , Tran, Anthony, Theel, Elitza S.

Mayo Clinic

Journal of Clinical Microbiology | April 27, 2017 | Volume: 55 | Issue: 7 | Pages: 2127-2136

10.1128/jcm.00580-17 | PMID 28446573 Get It

ABSTRACT Serologic evaluation for Zika virus (ZIKV) infection currently includes an initial screen using an anti-ZIKV IgM antibody capture enzyme-linked immunosorbent assay (MAC-ELISA) followed by supplemental testing of specimens with nonnegative results by a plaque reduction neutralization test (PRNT). We compared the performance characteristics of three ELISAs for the detection of IgM class antibodies to ZIKV, including the Centers for Disease Control and Prevention (CDC) Zika MAC-ELISA, the InBios ZIKV Detect MAC-ELISA, and the Euroimmun anti-Zika Virus IgM ELISA. Additionally, we present our initial experiences with ZIKV serologic testing from a national reference laboratory perspective. Using both retrospectively and prospectively collected specimens from patients with possible ZIKV infection, we show that the CDC and InBios MAC-ELISAs perform comparably to each other, with positive agreement, negative agreement, and interrater kappa values ranging from 87.5% to 93.1%, 95.7% to 98.5%, and 0.52 to 0.83, respectively. In contrast, comparison of the Euroimmun ZIKV ELISA to either the CDC or InBios MAC-ELISAs resulted in positive agreement, negative agreement, and interrater kappa values ranging from 17.9% to 42.9%, 91.7% to 98.6%, and 0.10 to 0.39, respectively. Among the 19 prospective samples submitted for PRNT, nine were negative, eight specimens had neutralizing antibodies to a flavivirus (unable to be identified), and one sample each was confirmed for ZIKV or dengue virus infection. This study highlights the ongoing challenges associated with serologic diagnosis of ZIKV infection. Although the availability of a commercial serologic test for ZIKV has greatly expanded the national capacity for such testing, the need to further characterize and improve these assays, particularly with regard to specificity, remains.
Enrichment of PI3K-AKT–mTOR Pathway Activation in Hepatic Metastases from Breast Cancer
Pierobon, Mariaelena , Ramos, Corinne, Wong, Shukmei , Hodge, K. Alex, Aldrich, Jessica, Byron, Sara A. , Anthony, Stephen P. , Robert, Nicholas J. , Northfelt, Donald W. , Jahanzeb, Mohammad , Vocila, Linda, Wulfkuhle, Julia , Gambara, Guido , Gallagher, Rosa I. , Dunetz, Bryant, Hoke, Nicholas N, Dong, Ting , Craig, David W. , Cristofanilli, Massimo , Leyland‐Jones, Brian , Liotta, Lance A. , O’Shaughnessy, Joyce , Carpten, John D. , Petricoin, Emanuel F. , Gallagher, Rosa I , Cristofanilli, Massimo

Mayo Clinic

Clinical Cancer Research | April 26, 2017 | Volume: 23 | Issue: 16 | Pages: 4919-4928

10.1158/1078-0432.ccr-16-2656 | PMID 28446508 Get It

Abstract Purpose: Little is known about the molecular signatures associated with specific metastatic sites in breast cancer. Using comprehensive multi-omic molecular profiling, we assessed whether alterations or activation of the PI3K–AKT–mTOR pathway is associated with specific sites of breast cancer metastasis. Experimental Design: Next-generation sequencing–based whole-exome sequencing was coupled with reverse-phase protein microarray (RPPA) functional signaling network analysis to explore the PI3K–AKT–mTOR axis in 32 pretreated breast cancer metastases. RPPA-based signaling data were further validated in an independent cohort of 154 metastatic lesions from breast cancer and 101 unmatched primary breast tumors. The proportion of cases with PI3K–AKT–mTOR genomic alterations or signaling network activation were compared between hepatic and nonhepatic lesions. Results: PIK3CA mutation and activation of AKT (S473) and p70S6K (T389) were detected more frequently among liver metastases than nonhepatic lesions (P < 0.01, P = 0.056, and P = 0.053, respectively). However, PIK3CA mutations alone were insufficient in predicting protein activation (P = 0.32 and P = 0.19 for activated AKT and p70S6K, respectively). RPPA analysis of an independent cohort of 154 tumors confirmed the relationship between pathway activation and hepatic metastasis [AKT (S473), mTOR (S2448), and 4EBP1 (S65); P < 0.01, P = 0.02, and P = 0.01, respectively]. Similar results were also seen between liver metastases and primary breast tumors [AKT (S473) P < 0.01, mTOR (S2448) P < 0.01, 4EBP1 (S65) P = 0.01]. This signature was lost when primary tumors were compared with all metastatic sites combined. Conclusions: Breast cancer patients with liver metastasis may represent a molecularly homogenized cohort with increased incidence of PIK3CA mutations and activation of the PI3K–AKT–mTOR signaling network. Clin Cancer Res; 23(16); 4919–28. ©2017 AACR.